Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAllergy Thera. Regulatory News (AGY)

Share Price Information for Allergy Thera. (AGY)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 5.25
Bid: 5.00
Ask: 5.50
Change: 0.00 (0.00%)
Spread: 0.50 (10.00%)
Open: 5.25
High: 5.25
Low: 5.00
Prev. Close: 5.25
AGY Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

U.S. regulatory update

28 Mar 2011 07:02

RNS Number : 6964D
Allergy Therapeutics PLC
28 March 2011
 



Monday 28 March 2011

 

 

Allergy Therapeutics plc

("Allergy Therapeutics" or "the Company")

 

U.S. regulatory update

 

 

 

Allergy Therapeutics plc (AIM: AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines is pleased to announce that it met with the U.S. Food and Drug Administration (FDA) for a productive discussion. The FDA has informed the Company of its intention to lift the clinical hold in order to allow the development of MATA-MPL© products to move forward. The Company expects to receive the formal communication from the FDA in the coming weeks.

 

 

Manuel Llobet, Chief Executive of Allergy Therapeutics, said:

 

"We are very pleased to have received positive feedback from the FDA and look forward to providing more information when the formal communication is received."

 

 

-Ends-

 

 

For further information

 

Allergy Therapeutics

+44 (0) 1903 845 820

Manuel Llobet, Chief Executive Officer

Ian Postlethwaite, Finance Director

www.allergytherapeutics.com

Nomura Code Securities

+44 (0) 207 776 1200

Juliet Thompson/ Clare Terlouw

Financial Dynamics

+44 (0) 207 831 3113

Ben Brewerton/ Susan Quigley

 

 

 

About Pollinex® Quattro

 

Pollinex® Quattro is a four injection therapeutic vaccine which is being developed for the treatment of allergic conditions which offers same season relief in as little as three weeks after treatment. It is a family of specific standardised vaccines representing a potentially extensive franchise for Allergy Therapeutics and is a novel entrant in the multibillion dollar global allergy market. It is currently available in Europe on a named patient basis.

 

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCDKODNFBKDDNB
Date   Source Headline
15th Jul 20227:00 amRNSTrading Update and Notice of Results
1st Jul 20227:00 amRNSAllergy Therapeutics at EAACI Congress 2022
26th May 20227:00 amRNSNick Wykeman to step down as CFO
23rd May 20227:00 amRNSAllergy Therapeutics at H.C. Wainwright Conference
25th Apr 20227:00 amRNSAllergy Therapeutics shares data at WAO-BSACI
7th Mar 20227:00 amRNSAllergy Therapeutics at Investor Meet Company
3rd Mar 20227:00 amRNSAllergy Therapeutics plc – Interim Results
1st Mar 20227:00 amRNSAllergy Therapeutics shares positive new data
24th Feb 20224:41 pmRNSSecond Price Monitoring Extn
24th Feb 20224:36 pmRNSPrice Monitoring Extension
24th Feb 20222:06 pmRNSSecond Price Monitoring Extn
24th Feb 20222:01 pmRNSPrice Monitoring Extension
2nd Feb 202211:05 amRNSSecures new revolving credit facility
1st Feb 20222:16 pmRNSTotal Voting Rights
26th Jan 20227:00 amRNSFDA clearance of IND application for VLP Peanut
24th Jan 20221:13 pmRNSHolding(s) in Company
13th Jan 20227:00 amRNSHalf Year Trading Update & Notice of Results
5th Jan 20228:47 amRNSTotal Voting Rights
25th Nov 20219:17 amRNSAllergy Therapeutics: Granting of Awards
23rd Nov 202112:54 pmRNSResult of AGM
11th Nov 20217:00 amRNSDirector Dealings
27th Oct 20217:00 amRNSCheryl MacDiarmid appointed to Board of Directors
25th Oct 20219:00 amRNSPrice Monitoring Extension
14th Oct 20219:24 amRNSHolding(s) in Company
7th Oct 20214:37 pmRNSAnnual Report and AGM Notification
23rd Sep 20217:00 amRNSPreliminary Results for Year ended 30 June 2021
16th Sep 20217:00 amRNSImmunoBON voted Most Innovative Product of 2021
13th Sep 20217:00 amRNSSecondary endpoints from VLP Peanut 001
9th Sep 20217:00 amRNSAllergy to Present at H.C. Wainwright Conference
7th Sep 20217:00 amRNSAllergy to host KOL webinar on VLP Peanut
3rd Aug 20217:00 amRNSSuccessful primary outcome of VLP Peanut 001
2nd Aug 202110:57 amRNSTotal Voting Rights
14th Jul 20217:00 amRNSTrading update for the year ended 30 June 2021
8th Jul 20217:00 amRNSAGY to present key scientific findings at EAACI
24th Jun 20217:00 amRNSTrading Update
1st Jun 20213:36 pmRNSTotal Voting Rights
10th May 20212:06 pmRNSSecond Price Monitoring Extn
10th May 20212:00 pmRNSPrice Monitoring Extension
6th May 20217:00 amRNSCompletion of treatment phase in G309 study
30th Apr 20215:47 pmRNSTotal Voting Rights
16th Apr 20217:00 amRNSAppointment of new Group auditors
31st Mar 20218:29 amRNSVesting of Awards under Long Term Incentive Plan
26th Mar 20214:39 pmRNSPledge of Shares
11th Mar 202112:13 pmRNSPledge of Shares
10th Mar 20214:40 pmRNSSecond Price Monitoring Extn
10th Mar 20214:35 pmRNSPrice Monitoring Extension
10th Mar 20212:05 pmRNSSecond Price Monitoring Extn
10th Mar 20212:00 pmRNSPrice Monitoring Extension
8th Mar 20217:00 amRNSAGY to Present at H.C. Wainwright Conference
3rd Mar 20217:00 amRNSInterim Results for six months ended 31 Dec 2020

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.